文献速递神经核医学肿瘤 PET/CT

68Ga-exendin-4 胰高血糖素样肽-1 受体 PET/CT 定位胰岛素瘤:一项真实世界单中心研究

Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-01

该研究基于前瞻性队列(NCT02560376)的回顾性分析,纳入357例患者(296例胰岛素瘤、61例非胰岛素瘤),评估68Ga-exendin-4 PET/CT定位胰岛素瘤的诊断效能。结果显示总体灵敏度94.93%、特异度100.00%、准确率95.79%,AUC 0.975,优于增强CT、MRI、超声内镜和99mTc-HYNIC-TOC SPECT/CT。作者认为68Ga-exendin-4 PET/CT是诊断胰岛素瘤的优选影像方法,尤其适用于散发性良性胰岛素瘤。

要点

  • 68Ga-exendin-4 PET/CT定位胰岛素瘤总体灵敏度94.93%、特异度100.00%、准确率95.79%。
  • AUC 0.975优于增强CT 0.873、MRI 0.825、超声内镜0.746和99mTc-HYNIC-TOC SPECT/CT 0.618。
  • 散发性良性胰岛素瘤病灶灵敏度95.47%、PPV 99.61%,散发性恶性及遗传综合征检出率较低。

核心结论

  • 68Ga-exendin-4 PET/CT是诊断胰岛素瘤的优选影像方法,尤其适用于散发性良性胰岛素瘤。

研究设计与样本

  • 本研究为前瞻性队列研究(NCT02560376)的回顾性分析,纳入内源性高胰岛素性低血糖且最终诊断明确的患者。
  • 共纳入357例患者,包括296例胰岛素瘤患者和61例非胰岛素瘤患者。
  • 诊断金标准为组织病理学(胰岛素瘤)或内分泌科住院后对高胰岛素性低血糖病因的明确临床诊断(非胰岛素瘤性低血糖)。
  • 收集了增强CT(含胰腺灌注扫描)、MRI、超声内镜和99mTc-HYNIC-TOC SPECT/CT的结果进行对比。

主要发现

  • 68Ga-exendin-4 PET/CT定位胰岛素瘤的总体灵敏度为94.93%(95%CI 91.78%~97.14%),特异度为100.00%(95%CI 94.13%~100%),准确率为95.79%(95%CI 93.16%~97.63%),PPV为100.00%(95%CI 98.32%~100%),NPV为80.26%(95%CI 71.29%~86.94%)。
  • 68Ga-exendin-4 PET/CT诊断胰岛素瘤的ROC曲线下面积为0.975(95%CI 0.953~0.988),优于增强CT(AUC 0.873,95%CI 0.833~0.906)、MRI(AUC 0.825,95%CI 0.773~0.869)、超声内镜(AUC 0.746,95%CI 0.652~0.825)和99mTc-HYNIC-TOC SPECT/CT(AUC 0.618,95%CI 0.562~0.672)。
  • 68Ga-exendin-4 PET/CT在散发性良性胰岛素瘤中的病灶灵敏度为95.47%(95%CI 92.22%~97.64%),PPV为99.61%(95%CI 99.60%~99.62%)。
  • 68Ga-exendin-4 PET/CT在散发性恶性胰岛素瘤中的病灶检出率为66.43%,在遗传综合征中的病灶检出率为68.04%。

关键数值与推荐

  • 68Ga-exendin-4 PET/CT定位胰岛素瘤的灵敏度94.93%(95%CI 91.78%~97.14%),特异度100.00%(95%CI 94.13%~100%)。
  • 68Ga-exendin-4 PET/CT的准确率95.79%(95%CI 93.16%~97.63%),PPV 100.00%(95%CI 98.32%~100%),NPV 80.26%(95%CI 71.29%~86.94%)。
  • 68Ga-exendin-4 PET/CT诊断胰岛素瘤的AUC为0.975(95%CI 0.953~0.988)。
  • 散发性良性胰岛素瘤的病灶灵敏度95.47%(95%CI 92.22%~97.64%),PPV 99.61%(95%CI 99.60%~99.62%)。
  • 散发性恶性胰岛素瘤和遗传综合征的病灶检出率分别为66.43%和68.04%。

临床怎么用

  • 作者认为68Ga-exendin-4 PET/CT是诊断胰岛素瘤的优选影像方法,尤其适用于散发性良性胰岛素瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Accurate preoperative localization is imperative for the treatment of insulinomas. Glucagon-like peptide-1 receptor (GLP-1R) imaging has demonstrated remarkable efficacy in localization of insulinomas. The aim of this study was to assess the diagnostic performance of GLP-1R PET/CT with 68Ga-exendin-4 in localization of insulinoma, and to provide evidence for clinical practice from a real-world study. METHODS: This is a retrospective analysis of our prospective cohort study of 68Ga-exendin-4 PET/CT in insulinoma (NCT02560376). Patients with endogenous hyperinsulinemic hypoglycemia and definite final diagnosis were enrolled. Results of contrast-enhanced CT (CECT) with pancreatic perfusion scan, MRI, endoscopic ultrasound, and 99mTc-HYNIC-TOC SPECT/CT were collected. The gold standard for diagnosis was histopathology (for insulinoma) or a definite clinical diagnosis of the etiology of hyperinsulinemic hypoglycemia after hospitalization in the endocrinology department (for non-insulinomatous hypoglycemia). RESULTS: A total of 357 patients (including 296 insulinoma patients and 61 non-insulinoma patients) with were included. The overall sensitivity, specificity, accuracy, PPV, and NPV of 68Ga-exendin-4 PET/CT in localizing insulinoma were 94.93% (95%CI, 91.78%˜97.14%), 100.00% (95%CI, 94.13%˜100%), 95.79% (95%CI, 93.16%˜97.63%), 100.00% (95%CI, 98.32%˜100%), 80.26% (95%CI, 71.29%˜86.94%), respectively. The area under the ROC of 68Ga-exendin-4 PET/CT for diagnosing insulinoma was 0.975 (95%CI, 0.953 ˜ 0.988), which was superior to that of CECT (AUC = 0.873 [95%CI, 0.833 ˜ 0.906]), MRI (AUC = 0.825 [95%CI, 0.773 ˜ 0.869]), EUS (AUC = 0.746 [95%CI, 0.652 ˜ 0.825]) and 99mTc-HYNIC-TOC SPECT/CT (AUC = 0.618 [95%CI, 0.562 ˜ 0.672]). The lesion-based sensitivity of 68Ga-exendin-4 PET/CT in sporadic benign insulinoma was 95.47% (95%CI, 92.22%˜97.64%), and the PPV was 99.61% (95%CI 99.60%˜99.62%). In contrast, the diagnostic efficacy of 68Ga-exendin-4 PET/CT was found to be less effective in cases of sporadic malignant insulinoma or inherited syndromes, yielding a lesion-based detection rate of 66.43% and 68.04%, respectively. CONCLUSION: 68Ga-exendin-4 PET/CT is a preferred imaging modality in diagnosing insulinoma, particularly in sporadic benign insulinomas.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang H, Pan Q, Liu S, et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40310561. doi:10.1007/s00259-025-07298-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。